Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity.
Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J, Sanclemente M, Lapek J, Nguyen L, Niessen S, Dann S, VanArsdale T, Barbacid M, Miller N, Spencer SL.
Arora M, et al.
Cell. 2023 Jun 8;186(12):2628-2643.e21. doi: 10.1016/j.cell.2023.05.013. Epub 2023 Jun 1.
Cell. 2023.
PMID: 37267950
CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, we use several CDK2 inhibitors in clinical development to interrogate CDK2 substrate phosphorylation, cell-cycle progression, and drug adaptation in preclinical models. ...
CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, we use several CDK2 inhibitors in clinic …